By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Current study results on Biotechnology have been published. According to news originating from Guangdong, People's Republic of China, by NewsRx correspondents, research stated, "FHL2 (Four and a half LIM-only protein 2) has been identified as an oncogene in colon cancer and suppression of FHL2 induces cell differentiation and tumorigenesis in colon cancer cell lines. The aim of this study was to develop a novel and effective approach to knockdown FHL2, which can serve as a promising target of colon cancer therapy."
Our news journalists obtained a quote from the research from Guangzhou Medical University, "Recombinant adeno-associated virus (rAAV) was generated bearing with FHL2-shRNA and transfected into LoVo cells. Cell cycle and growth were assessed. The interaction between FHL2 and G0/G1 cell cycle and growth was evaluated by flow cytometry, western blot analysis and WST-1 assay. We showed that suppression of FHL2 by rAAV-shRNA induced G0/G1 cell cycle arrest and inhibited cell growth. Apoptosis-related proteins and their activity was investigated at the same time. rAAV-FHL2-shRNA activated intrinsic and extrinsic apoptotic pathways and increased cell susceptibility to apoptotic stimuli by 5-FU. Moreover, a xenograft model was established to explore rAAV-FHL2-shRNA with 5-FU mediated tumorigenesis in vivo. A strong anti-tumorigenic effect of rAAV-FHL2-shRNA was shown in nude mice and this antitumor effect was enhanced when combined with 5-FU treatment."
According to the news editors, the research concluded: "These findings implicate FHL2 as a cell cycle and growth modulator and thus inhibit apoptosis in colon cancer cells. rAAV-shRNA-FHL2 may serve as a novel and potent therapeutic or 5-FU co-therapeutic agent for colon cancer."
For more information on this research see: A novel colon cancer gene therapy using rAAV-mediated expression of human shRNA-FHL2. International Journal of Oncology, 2013;43(5):1618-1626. International Journal of Oncology can be contacted at: Spandidos Publ Ltd, Pob 18179, Athens, 116 10, Greece (see also technology.html">Biotechnology).
The news correspondents report that additional information may be obtained from Y. Wu, Guangzhou Med Univ, Affiliated Hosp 1, Dept. of Gastroenterol, Guangzhou 510210, Guangdong, People's Republic of China. Additional authors for this research include Z. Guo, D. Zhang, W.J. Zhang, Q.Q. Yan, X.P. Shi, M.N. Zhang, Y.Y. Zhao, Y.L. Zhang, B. Jiang, T.M. Cheng, Y. Bai and J.D. Wang.
Keywords for this news article include: Asia, Biotechnology, Genetics, Oncology, Guangdong, Colon Cancer, Bioengineering, Cancer Gene Therapy, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC